| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
May 17, 2012Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
PARIS--(BUSINESS WIRE)--May. 17, 2012-- Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from...
-
May 16, 2012New Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing...
-
May 16, 2012Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: MEDTRONIC IN.PACT DRUG-ELUTING...
-
May 15, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 15, 2012-- Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to...
-
May 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 26, 2012ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Mar 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
-
Mar 24, 2012Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
-
Mar 1, 2012“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 1, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the...
-
Feb 29, 2012World’s First Insulin Pump with Low Glucose Suspend Showed Reduces Time Spent in Low Threshold Range
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 29, 2012-- In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE...
-
Feb 21, 2012Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
-
Feb 17, 2012Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 17, 2012-- Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (
-
Feb 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2012 on Tuesday, February 21,...
-
Feb 8, 2012New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 8, 2012-- Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. (NYSE:MDT) today announced the...
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...
-
Dec 10, 2011
MINNEAPOLIS, Nov 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2012 on Tuesday, November 22,...
-
Dec 9, 2011Neurostimulator with Innovative Motion Sensor Technology Was Recently Approved by the FDA for the Management of Chronic Pain
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 9, 2011-- Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStim™ with...
-
Nov 20, 2011Revenue of $4.1 Billion Grew 3% on a Constant Currency Basis, 6% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2012, which ended October 28, 2011. The company...
-
Nov 17, 2011
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE:MDT) and Bain Capital, a leading global private investment firm, today announced they have entered into a definitive...
-
Nov 17, 2011Neurostimulator Uses Innovative Motion Sensor Technology to Provide Patient Comfort and Convenience
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™...
-
Nov 9, 2011Study Will Evaluate Accuracy of Latest Innovation to Help People with Diabetes Improve Glucose Control
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in...
-
Nov 9, 2011
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal...
-
Nov 8, 2011Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device's Consistently Positive Performance Across Multiple Clinical Studies
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT)...
-
Nov 8, 2011Final Five-Year Follow-up of Randomized ENDEAVOR IV Trial Shows Durable Safety and Efficacy of Endeavor DES, with Comparatively Lower Rates of Cardiac Death/Myocardial Infarction and Very Late Stent Thrombosis
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- New research findings released at TCT 2011 show that the Endeavor(R) zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed...
-
Oct 31, 2011Assurant(R) Cobalt Iliac Stent Features Novel Alloy and Modular Design; Augments Company's Peripheral Portfolio with Balloon-Expandable Option
MINNEAPOLIS, Oct 31, 2011 (BUSINESS WIRE) -- Advancing the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced approval by the U.S. Food and Drug Administration...
-
Oct 28, 2011A Critical Step Toward the Development of an Artificial Pancreas, Low Glucose Suspend Aims to Reduce Hypoglycemia
MINNEAPOLIS, Oct 28, 2011 (BUSINESS WIRE) -- In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA)...
-
Oct 27, 2011
MINNEAPOLIS, Oct 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against...
-
Oct 26, 2011U.S. Clinical Trial of Symplicity(R) Renal Denervation System(TM) Enrolls First Patient
MINNEAPOLIS, Oct 26, 2011 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity(R) Renal Denervation...
-
Oct 10, 2011First Ever Randomized, Controlled Clinical Trial in Persistent Atrial Fibrillation (AF) Patients
VENICE, Italy & MINNEAPOLIS, Oct 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical...
-
Sep 20, 2011
MINNEAPOLIS, Sep 20, 2011 (BUSINESS WIRE) -- Following are statements from Herb Riband, Medtronic vice president of external affairs, and Dr. Jacob Gayle, vice president of Medtronic Foundation...
-
Aug 31, 2011Medtronic Expands Role in Advanced Energy Surgical Technologies
MINNEAPOLIS, Aug 31, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of two privately-held companies, PEAK Surgical, Inc. and Salient...
-
Aug 23, 2011Revenue of $4 Billion Driven by International Growth of 7% on a Constant Currency Basis; 19% as Reported
MINNEAPOLIS, Aug 23, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2012, which ended July 29, 2011. The Company...
-
Aug 18, 2011New Offering Provides Therapy Option to Previously Unserved Patients with Larger Aortic Valves
MINNEAPOLIS, Aug 18, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for its 31mm Medtronic CoreValve(R) System, the only...
-
Aug 15, 2011InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA
MINNEAPOLIS, Aug 15, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using...
-
Aug 12, 2011
MINNEAPOLIS, Aug 12, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2012 on Tuesday, August 23, 2011....
-
Aug 5, 2011
MINNEAPOLIS, Aug 05, 2011 (BUSINESS WIRE) -- Medtronic investors and other interested parties are invited to participate in a live video webcast of the Medtronic Annual Shareholder Meeting on...
-
Aug 3, 2011First of its Kind Post-Review Website to Provide Scientific Access to Full Clinical Data
MINNEAPOLIS, Aug 03, 2011 (BUSINESS WIRE) -- Medtronic, Inc. [NYSE: MDT] announced today that it has provided a grant to Yale University to conduct two fully independent, third-party systematic...
-
Aug 1, 2011Investigational Second-Generation Device Reinforces Medtronic's Commitment to Innovative Implantable Cardiac Devices Designed for Use in MRI Environment
MINNEAPOLIS, Aug 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval for its Investigational Device Exemption (IDE) application...
-
Jul 21, 2011Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall
MINNEAPOLIS, Jul 21, 2011 (BUSINESS WIRE) -- Twenty-five long-distance runners who benefit from medical technology will be honored as "Medtronic Global Heroes" when they run the Medtronic Twin...
-
Jul 11, 2011Patient Enrollment in U.S. Clinical Trial of Renal Denervation with Symplicity(R) Catheter System(TM) for Treating Resistant Hypertension to Start Soon
MINNEAPOLIS, Jul 11, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY...
-
Jul 8, 2011Update to July 2009 Letter to Healthcare Professionals
MINNEAPOLIS, Jul 08, 2011 (BUSINESS WIRE) -- As part of its ongoing commitment to keep patients and physicians informed about product performance and safety, Medtronic, Inc. (NYSE: MDT) is issuing...
-
Jul 1, 2011Europe first in line to receive Medtronic's innovative product
MEMPHIS, Tenn., Jul 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the European launch of the CD HORIZON(R) Fenestrated Screw Spinal System, which is used in conjunction...
-
Jun 28, 2011The CareLink(TM) Mobile Application Offers Direct Mobile Access to Data on the Medtronic CareLink(R) Network
MINNEAPOLIS, Jun 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced the launch of Medtronic's first mobile application for use with implantable cardiac devices. As health care...
-
Jun 25, 2011STAR 3 Continuation Data, Low Glucose Suspend and Patient Reported Outcomes Highlighted at American Diabetes Association's 71st Scientific Sessions
SAN DIEGO, Jun 25, 2011 (BUSINESS WIRE) -- Research presented at the American Diabetes Association's 71st Scientific Sessions (ADA) this week adds to the clinical evidence for Medtronic's...
-
May 24, 2011Record Fourth Quarter Revenue of $4.3 Billion Driven by Strong International Growth of 12%
MINNEAPOLIS, May 24, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 29, 2011. Medtronic recorded fiscal...
-
May 19, 2011New Access for Aortic Valve Replacement Achieves High Procedural Success in Italian Study of High Risk Patients
PARIS, May 19, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today issued a statement on results of clinical data presented at EuroPCR 2011 that show the Medtronic CoreValve(R) System,...